Call Us: 1.800.873.5297

By

Xarelto Expanded Use Denied Again by FDA

According to Reuters, the FDA once again declined to approve wider uses of the prescription drug Xarelto® (Rivaroxaban) late last month. Currently, the drug’s biggest approved use is to prevent blood clots and strokes in patients with an irregular heartbeat called atrial fibrillation. Recently, the drug’s co-marketers—Bayer AG and Johnson & Johnson—tried to expand the drug’s use. The companies sought approval from the U.S. Food and Drug Administration (FDA) to market Xarelto® for prevention of new heart attacks, strokes, and death, in patients with acute coronary syndrome (ACS), as well as for prevention of coronary events due to stent thrombosis.

Johnson & Johnson first sought approval for this expanded use in late 2011. The FDA rejected the application, citing missing data. The company retrieved some missing data but the FDA has once again declined to approve the drug. According to Reuters, the additional data did not alter the FDA’s view that the benefit of the drug was not shown to outweigh an increased risk of bleeding. The denial by the FDA comes after receiving over 600 reports on the drug’s adverse events, including serious and uncontrolled bleeding.

Xarelto® (Rivaroxaban) is a blood thinning medication alleged to cause serious and uncontrolled internal bleeding, particularly gastrointestinal bleeding, that could result in severe injuries, or even death. Xarelto® is part of a class of drugs called New Oral Anticoagulants (NOACs). This class of NOACs has been marketed as the next generation of blood-thinning drugs designed to replace warfarin – which has been on the United States market for more than 50 years.

If you or a loved one has suffered serious internal bleeding injuries after using Xarelto®, please contact the bad drug attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

 

The choice of a lawyer is an important decision and should not be based solely on advertisements.

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.